Facteurs prédictifs de non réponse au vismodégib dans les carcinomes basocellulaires localement avancés
H. Marescassier(Centre Hospitalier Universitaire de Poitiers), M. Masson Regnault(Polyclinique de Franche Comté), M. Beylot‐Barry(Université de Bordeaux), E. Hainaut(Centre Hospitalier Universitaire de Poitiers), L. Dousset(Centre Hospitalier Universitaire de Bordeaux), C. Bédane(Central Michigan University), L. Vaillant(Centre Hospitalier Universitaire de Tours), P. Celérier(Centre Hospitalier de La Rochelle)
Cited by 0
Related Papers
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
|Journal of Clinical Oncology|2015|419
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study
|Annals of the Rheumatic Diseases|2017|302
Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.
|PubMed|2000|267
Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response
|Science Translational Medicine|2013|246